Treatment for Ovarian Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Ovarian Cancer
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

This trial is testing a treatment for women with a certain type of ovarian cancer that has come back. The treatment is surgery to remove as much of the cancer as possible, followed by a heated chemotherapy treatment.

Eligible Conditions
  • Ovarian Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: through study completion, an average of 6 years (patients will be followed for 6 years after treatment completion

Year 6
To estimate progression-free survival (PFS) after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

0 Treatment Group

30 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase 2

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 6 years (patients will be followed for 6 years after treatment completion

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,802 Previous Clinical Trials
1,788,869 Total Patients Enrolled
40 Trials studying Ovarian Cancer
15,935 Patients Enrolled for Ovarian Cancer
Michael Frumovitz, MDPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
180 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Female Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have histologically or cytologically confirmed recurrent primary mucinous ovarian cancer.
Creatinine must be less than 1.5 mg/dL.
You are able to understand the nature and purpose of the study and to give informed consent.